TransCode Therapeutics, Inc. Announces Closing of Public Offering Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to

TransCode Therapeutics, Inc. Announces Pricing of Public Offering Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering TransCode Therapeutics closes public offering

TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference....